121 related articles for article (PubMed ID: 2351626)
1. Plasma and dialysate levels of pefloxacin and its metabolites in CAPD patients with peritonitis.
Rose TF; Bremner DA; Collins J; Ellis-Pegler R; Isaacs R; Richardson R; Small M
J Antimicrob Chemother; 1990 Apr; 25(4):657-64. PubMed ID: 2351626
[TBL] [Abstract][Full Text] [Related]
2. Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nikolaidis P; Walker SE; Dombros N; Tourkantonis A; Paton TW; Oreopoulos DG
Perit Dial Int; 1991; 11(1):59-63. PubMed ID: 2049424
[TBL] [Abstract][Full Text] [Related]
3. Oral pefloxacin mesylate in the treatment of continuous ambulatory peritoneal dialysis associated peritonitis: an open non-comparative study.
Rose TF; Ellis-Pegler R; Collins J; Small M
J Antimicrob Chemother; 1990 May; 25(5):853-9. PubMed ID: 2373667
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics].
Denis F; Mounier M; Lagarde C; Benevent D
Pathol Biol (Paris); 1987 May; 35(5):652-5. PubMed ID: 3302879
[TBL] [Abstract][Full Text] [Related]
5. Oral pefloxacin in the treatment of CAPD peritonitis.
Tan HW; Kon SP; Chua CT; Ngeow NF
Med J Malaysia; 1992 Jun; 47(2):128-33. PubMed ID: 1494333
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
Choi KC; Jeong TK; Lee SC; Kim SW; Kim NH; Lee KY
Adv Perit Dial; 1998; 14():173-9. PubMed ID: 10649719
[TBL] [Abstract][Full Text] [Related]
7. Peritonitis during continuous ambulatory peritoneal dialysis. Treatment with pefloxacin: first results and pharmacokinetics.
Benzakour M; Lagarde C; Benevent D; Mounier M; Denis F
Nephron; 1988; 50(2):175-6. PubMed ID: 3065665
[No Abstract] [Full Text] [Related]
8. Management of peritonitis related to chronic ambulatory peritoneal dialysis (CAPD) using two daily intraperitoneal injections of 400 mg pefloxacin.
Ragnaud JM; Roche-Bezian MC; Dupon M; Wone C
Chemioterapia; 1987 Jun; 6(2 Suppl):481-3. PubMed ID: 3509476
[No Abstract] [Full Text] [Related]
9. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD.
Pannekeet MM; Zemel D; Koomen GC; Struijk DG; Krediet RT
Perit Dial Int; 1995; 15(6):217-25. PubMed ID: 7578497
[TBL] [Abstract][Full Text] [Related]
10. Association between nitric oxide and oxidative stress in continuous ambulatory peritoneal dialysis patients with peritonitis.
Duranay M; Yilmaz FM; Yilmaz G; Akay H; Parpucu H; Yücel D
Scand J Clin Lab Invest; 2007; 67(6):654-60. PubMed ID: 17852815
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD).
Ludlam HA; Barton I; White L; McMullin C; King A; Phillips I
J Antimicrob Chemother; 1990 May; 25(5):843-51. PubMed ID: 2197264
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal vancomycin/oral pefloxacin versus intraperitoneal vancomycin/gentamicin in the treatment of continuous ambulatory peritoneal dialysis peritonitis.
Lye WC; Lee EJ; van der Straaten J
Perit Dial Int; 1993; 13 Suppl 2():S348-50. PubMed ID: 8399607
[TBL] [Abstract][Full Text] [Related]
13. Can the risk of peritonitis be predicted for new continuous ambulatory peritoneal dialysis (CAPD) patients?
Coles GA; Minors SJ; Horton JK; Fifield R; Davies M
Perit Dial Int; 1989; 9(1):69-72. PubMed ID: 2488186
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of peritonitis in continuous ambulatory peritoneal dialysis with a combination of fosfomycin and pefloxacin].
Michel C; Viron B; Delisle F; Lependoven C; Mignon F
Pathol Biol (Paris); 1989 Apr; 37(4):269-71. PubMed ID: 2660079
[TBL] [Abstract][Full Text] [Related]
15. Multiple-dose-kinetics of ofloxacin after intraperitoneal application in CAPD patients.
Kampf D; Borner K; Hain H; Conrad W
Perit Dial Int; 1991; 11(4):317-21. PubMed ID: 1751596
[TBL] [Abstract][Full Text] [Related]
16. Is interleukin-6 concentration in the dialysate of continuous ambulatory peritoneal dialysis patients a prognostic parameter in peritonitis?
Fiedler R; Schneider I; Fischer K; Deuber HJ; Osten B
Adv Perit Dial; 2001; 17():159-62. PubMed ID: 11510267
[TBL] [Abstract][Full Text] [Related]
17. Newer quinolones in the treatment of continuous ambulatory peritoneal dialysis (CAPD) related infections.
Nikolaidis P
Perit Dial Int; 1990; 10(2):127-33. PubMed ID: 2085597
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
Yang CW; Hwang TL; Wu CH; Lai PC; Huang JY; Yu CC; Shyr MH; Huang CC
Nephrol Dial Transplant; 1996 Dec; 11(12):2466-71. PubMed ID: 9017624
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of clindamycin in the plasma and dialysate after intraperitoneal administration of clindamycin phosphoester to patients on continuous ambulatory peritoneal dialysis: an open-label, prospective, single-dose, two-institution study.
Chang MJ; Namgung H; Choi HD; Song YR; Kim SG; Oh JM; Shin WG
Basic Clin Pharmacol Toxicol; 2012 Jun; 110(6):504-9. PubMed ID: 22151828
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis.
Zhu W; Fang X; Zheng J; Ke Y; He Q; Cui T; Chen B; Tian L
Ren Fail; 2023; 45(2):2285873. PubMed ID: 38044852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
